STOCK TITAN

TransMedics to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

ANDOVER, Mass., Aug. 29, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the management team will participate in a fireside chat at the upcoming Morgan Stanley 20th Annual Global Healthcare Conference at the Sheraton New York. The fireside chat will take place on Monday, September 12, 2022, at 11:40 a.m. Eastern Time.

Event: Morgan Stanley 20th Annual Global Healthcare Conference
Date: Monday, September 12, 2022
Time: 11:40 a.m. ET

A live and archived webcast of the fireside chat will be available on the "Investors" section of the TransMedics website at https://investors.transmedics.com/

About TransMedics Group, Inc.

TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure.

Investor Contact:
Brian Johnston
332-895-3222
Investors@transmedics.com

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/transmedics-to-participate-in-the-morgan-stanley-20th-annual-global-healthcare-conference-301613980.html

SOURCE TransMedics Group, Inc.

Transmedics Group Inc

NASDAQ:TMDX

TMDX Rankings

TMDX Latest News

TMDX Stock Data

Surgical and Medical Instrument Manufacturing
Manufacturing
Link
Medical Specialties, Health Technology, Manufacturing, Surgical and Medical Instrument Manufacturing
US
Andover

About TMDX

transmedics inc. is the world’s leader in portable ex-vivo perfusion and assessment of donor organs for transplantation. the company was founded to address the need for more and better organs for transplantation, and is focused on transforming the standard of care – increasing organ utilization, improving patient outcomes, and reducing transplant costs throughout the heath care system. the ocs™ lung and ocs™ heart systems are ce-marked and in commercial use outside the us, and are currently being reviewed by the fda for u.s. market access. the ocs™ liver is in an fda pivotal trial (the ocs™ liver protect trial) in the united states and a ce-mark trial in (the revive trial) in europe.